What is the role of mitochondrial membranes in the pathogenesis of atherosclerosis?
Best insight from top research papers
Mitochondrial dysfunction plays a significant role in the pathogenesis of atherosclerosis. It is involved in lipid accumulation, inflammation, and structural changes in the arterial wall . Mitochondria are responsible for the production of reactive oxygen species (ROS) during oxidative stress, which can lead to the formation of oxidized low-density lipoprotein (LDL) . Mitochondrial dysfunction is associated with chronic human diseases, including cardiovascular disorders, and has been found to be present in the affected areas of the arterial wall . It contributes to oxidative stress, chronic inflammation, and intracellular lipid accumulation, all of which are key processes in atherosclerosis . Mitochondria also play a role in controlling inflammation through the release of mitochondrial components, such as mitochondrial DNA (mtDNA), which act as danger signals when recognized by innate immune receptors . Understanding the pathways behind mitochondrial dysfunction and inflammation in atherosclerosis is crucial for developing alternative or complementary treatments .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
9 Citations | The provided paper does not specifically mention the role of mitochondrial membranes in the pathogenesis of atherosclerosis. |
| The paper does not specifically mention the role of mitochondrial membranes in the pathogenesis of atherosclerosis. | |
22 Citations | The paper does not provide specific information about the role of mitochondrial membranes in the pathogenesis of atherosclerosis. |
33 Citations | The provided paper does not specifically discuss the role of mitochondrial membranes in the pathogenesis of atherosclerosis. |
8 Citations | The provided paper does not specifically mention the role of mitochondrial membranes in the pathogenesis of atherosclerosis. |
Related Questions
What are the specific mechanisms by which Reactive Oxygen Species contribute to the development of atherosclerosis?5 answersReactive Oxygen Species (ROS) play a crucial role in the development of atherosclerosis through various mechanisms. Firstly, ROS contribute to oxidative stress, a major risk factor for atherosclerosis, by activating pro-atherogenic processes like inflammation, endothelial dysfunction, and altered lipid metabolism. Additionally, mitochondrial ROS (mtROS) produced by macrophages drive macrophage activation and promote foam cell formation, a key step in atherosclerosis progression. Oxidized LDL (oxLDL), a product of LDL oxidation, enhances foam cell formation and atherosclerotic plaque development through various pathophysiological changes, including endothelial dysfunction, monocyte chemotaxis, and smooth muscle cell proliferation. Furthermore, Chinese herbal medicine has been shown to regulate intracellular ROS and exert antiatherosclerosis effects, highlighting the importance of ROS modulation in atherosclerosis treatment.
What are the specific mechanisms by which calcium homeostasis between the ER and mitochondria affects the development of atherosclerosis?5 answersThe interaction between calcium homeostasis in the endoplasmic reticulum (ER) and mitochondria plays a crucial role in the pathogenesis of atherosclerosis. Disruption of mitochondrial redox homeostasis in endothelial cells (ECs) can lead to chronic inflammation, a key contributor to atherosclerosis development. Mitochondria are involved in various cellular processes, including calcium homeostasis, and under stress conditions, imbalances in calcium levels can occur, leading to mitochondrial dysfunction and inflammation. Additionally, mitochondrial dysfunction associated with chronic disorders like atherosclerosis involves oxidative stress, chronic inflammation, and intracellular lipid accumulation, all of which are influenced by mitochondrial dysfunction and calcium signaling. Therefore, the intricate interplay between ER-mitochondria calcium homeostasis and mitochondrial function is a critical factor in the progression of atherosclerosis.
What is the role of oxLDL in atherosclerosis?5 answersOxidized low-density lipoprotein (oxLDL) plays a crucial role in atherosclerosis by promoting inflammation, oxidative stress, and vascular dysfunction. Studies have shown that oxLDL, through its interaction with the lectin-like oxLDL receptor-1 (LOX-1), leads to increased inflammation, oxidative stress, and altered vasoreactivity, contributing to atherosclerotic plaque formation. Additionally, oxLDL induces a toxic environment for macrophages and foam cells, leading to their dysfunction and death, which accelerates early plaque growth. Furthermore, the measurement of circulating oxLDL levels has been proposed as a potential biomarker for cardiovascular disease diagnosis, prognosis, and therapy assessment, highlighting the significance of oxLDL in atherosclerosis progression and management.
What are the potential therapeutic targets for modulating mitochondrial biogenesis in the prevention of atherosclerosis?7 answersMitochondrial biogenesis and its regulation present a promising avenue for therapeutic intervention in the prevention of atherosclerosis, a complex pathology underpinned by metabolic dysfunction and chronic inflammation. The potential therapeutic targets for modulating mitochondrial biogenesis in atherosclerosis prevention encompass a broad spectrum of strategies aimed at correcting mitochondrial dysfunction, mitigating oxidative stress, and enhancing mitochondrial DNA (mtDNA) integrity.
Firstly, targeting mitochondrial dynamics through the modulation of fusion and fission processes can address mitochondrial dysfunction, a key factor in the progression of cardiovascular diseases (CVD) and atherosclerosis. Mitochondrial homeostasis, maintained through these dynamic processes, is crucial for cellular health and function, suggesting that interventions aimed at enhancing mitochondrial fusion or inhibiting excessive fission could mitigate atherosclerotic progression.
Secondly, the application of mitochondria-targeted therapeutic agents and gene therapy technologies offers a direct approach to correcting metabolic disorders associated with mitochondrial dysfunction in CVD. These strategies focus on enhancing mitochondrial energy metabolism, thereby potentially preventing the progression of atherosclerosis.
Furthermore, mitochondrial transplantation and the delivery of polymer-functionalized mitochondria have emerged as innovative strategies. These approaches aim at reprogramming macrophage metabolism to reduce inflammation and plaque progression, highlighting the therapeutic potential of directly modulating mitochondrial function within atherosclerotic plaques.
Additionally, the inhibition of mitochondrial fission through DRP1 inhibitors has shown promise in alleviating atherosclerosis by reducing M1 macrophage polarization and suppressing the mito-ROS/NLRP3-mediated inflammatory pathway, indicating another target for therapeutic intervention.
Moreover, lipid-based gene delivery to mitochondria represents an interesting strategy for correcting mtDNA damage in macrophages, a key event in atherogenesis. This approach underscores the potential of targeting mtDNA integrity as a means to prevent or mitigate atherosclerosis.
Lastly, the exploration of mitochondria-targeting antioxidant therapies based on the significant role of oxidative stress and mitochondrial dysfunction in vascular disease offers a promising direction. These therapies aim at reducing oxidative stress and chronic inflammation, thereby impacting the development of atherosclerotic plaques.
In summary, the prevention of atherosclerosis through the modulation of mitochondrial biogenesis encompasses a multifaceted approach, targeting mitochondrial dynamics, enhancing mitochondrial metabolism, correcting mtDNA damage, and reducing oxidative stress and inflammation. These strategies collectively offer a promising outlook for the development of effective therapeutic interventions against atherosclerosis.
What is the role of mitochondria in metabolic syndrome?4 answersMitochondria play a crucial role in the development and progression of metabolic syndrome (MetS). MetS is characterized by insulin resistance, abdominal adiposity, elevated blood pressure, and perturbations in lipid metabolism. Mitochondrial dysfunction, including abnormal mitochondrial quality and impaired mitochondrial energy production, has been linked to the pathogenesis of MetS. Dysfunctional mitochondria contribute to metabolic disorders associated with MetS, such as obesity, insulin resistance, and type 2 diabetes mellitus. Mitochondrial dysfunction in MetS is associated with mechanisms such as mitochondrial energy deprivation, calcium disorder, and reactive oxygen species (ROS) imbalance. Additionally, mitochondrial DNA (mtDNA) mutations and abnormalities in mitochondrial dynamics have been implicated in the development of MetS. Understanding the role of mitochondria in MetS may provide novel therapeutic targets for the management of this complex pathological condition.
How do mitochondria contribute to myocardial infarction?2 answersMitochondria contribute to myocardial infarction by promoting cardiomyocyte death through various mechanisms. One mechanism involves the communication between mitochondria and the endoplasmic reticulum, which leads to cardiomyocyte damage. Another mechanism is the generation of reactive oxygen species (ROS) within mitochondria, which can induce oxidative damage and mitochondrial dysfunction. Mitochondrial dysfunction during acute myocardial ischemia-reperfusion injury (IRI) plays a crucial role in the development of heart failure. Additionally, mitochondrial quality control mechanisms, such as mitochondrial unfolded protein response, mitophagy, biogenesis, and fusion-fission dynamics, are important for maintaining proper mitochondrial function and cell survival in the context of myocardial infarction and heart failure. Overall, targeting mitochondrial dysfunction and improving mitochondrial quality control may have therapeutic potential for reducing myocardial infarct size and improving outcomes in patients with myocardial infarction and heart failure.